<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01806974</url>
  </required_header>
  <id_info>
    <org_study_id>RC12_0172</org_study_id>
    <nct_id>NCT01806974</nct_id>
  </id_info>
  <brief_title>Consequences of Anti-interleukin 6 Immunotherapy Treatment for Rheumatoid Arthritis on Periodontium</brief_title>
  <acronym>ParoPAR</acronym>
  <official_title>Multicenter, Prospective Study, on the Consequences of Anti-interleukin 6 Immunotherapy Treatment for Rheumatoid Arthritis on: - Healthy and Pathological Periodontium - The Level of Expression of Some Markers of Inflammation and Periodontal Pathogenic Bacteria in Periodontal Sulci and Periodontal Pockets</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rheumatoid arthritis and periodontitis are two inflammatory diseases that share many
      pathophysiological similarities as some inflammatory mediators like TNF-alpha, IL-1, Il-6,
      Il-17, Il-12 et Il-17, RANK-L, or OPG The most severe or progressive forms of rheumatoid
      arthritis require in 10-30% of cases, the use of biotherapies such as anti-TNF-alpha, anti
      CD-20 and anti-lL-6. All these treatments results in, among other things, an increased risk
      of infection, both viral and bacterial.

      These new biotherapies could have an impact on periodontal status

        -  either by favouring sub gingival colonization of root surfaces by periodontal pathogenic
           bacteria and initiate periodontitis or exacerbate pre-existing periodontitis,

        -  or a positive modulation of the host response by inhibiting bone resorption of the
           alveolar process.

      To date, very few studies have been conducted on this subject which is really a translational
      research, involving several medical specialties.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    as the recruitment rate was very low, a futility study was conducted and it was decided to
    discontinue inclusions
  </why_stopped>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical attachment level</measure>
    <time_frame>6 month</time_frame>
    <description>Gain or loss obtained by periodontal probing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Detection of periodontopathogenic germs</measure>
    <time_frame>6 month</time_frame>
    <description>Detection of periodontopathogenic germs by RT - PCR - Q wich the bacterial samples will be made at the outset of the study and 6 month after the beginning of anti IL6 treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of periodontopathogenic germs</measure>
    <time_frame>6 month</time_frame>
    <description>Quantification of periodontopathogenic germs by RT - PCR - Q wich the bacterial samples will be made at the outset of the study and 6 month after the beginning of anti IL6 treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection of inflammation markers in the gingival fluid</measure>
    <time_frame>6 month</time_frame>
    <description>Detection and quantification of inflammation markers in the gingival fluid : IL-1, IL-6, IL-8, IL-10, IL-12, IL-15, IL-17, TGF- beta, TNF-alpha, IL-4 et IFn-gamma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of inflammation markers in the gingival fluid</measure>
    <time_frame>6 month</time_frame>
    <description>Quantification of inflammation markers in the gingival fluid : IL-1, IL-6, IL-8, IL-10, IL-12, IL-15, IL-17, TGF- beta, TNF-alpha, IL-4 et IFn-gamma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of inflammation</measure>
    <time_frame>6 month</time_frame>
    <description>Assessment of inflammation through Bleeding On Probing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of oral hygiene level</measure>
    <time_frame>6 month</time_frame>
    <description>Assessment of oral hygiene level with plaque Index</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Periodontitis</condition>
  <arm_group>
    <arm_group_label>patient with parodontitis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patient with rheumatoid arthritis and pparodontitis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient without parodontitis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patient with rheumatoid arthritis but periodontally healthy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>oral exam and</intervention_name>
    <description>The study will be conducted with patient presenting a rheumatoid arthritis and for which an anti IL6 biotherapy treatment is planned. Each patient will benefit a record oral exam that will evaluate his periodontal status and on a possible periodontitis associated. Bacterial samples and cytokine will be realized (in defined periodontal pocket or in the most affected periodontal pocket depending of the periodontal status of patients) before the IL6 biotherapy and 6 month after. A periodontal charting will be realized at the same time.</description>
    <arm_group_label>patient with parodontitis</arm_group_label>
    <arm_group_label>Patient without parodontitis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient over 18 years presenting a rheumatoid arthritis and for which an anti IL6
             biotherapy treatment is prescribed.

          -  At least 18 permanent teeth in the mouth at least 3 teeth with a healthy periodontal
             status

          -  Having expressed their written free and informed consent

        Exclusion Criteria:

          -  Hypersensitivity to any of the following components : tocilizumab, saccharose,
             polysorbate 80, phosphate disodique dodécahydrate, phosphate monosodique dehydrate

          -  Severe or active infections

          -  Systemic Pathology affecting the immune system including Sjögren's syndrome

          -  Surgery in the previous month

          -  HIV positive

          -  Alcoholic

          -  Toxicoman

          -  Antibiotic treatment in the last 2 months

          -  Legally protected patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Assem SOUEIDAN</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nantes UH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brest University Hospital</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nantes University Hospital</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2013</study_first_submitted>
  <study_first_submitted_qc>March 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2013</study_first_posted>
  <last_update_submitted>November 2, 2015</last_update_submitted>
  <last_update_submitted_qc>November 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Periodontitis</keyword>
  <keyword>rheumatoid arthritis</keyword>
  <keyword>anti-interleukin 6</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>inflammation</keyword>
  <keyword>bacteria</keyword>
  <keyword>periodontal sulci</keyword>
  <keyword>periodontal pockets</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Periodontitis</mesh_term>
    <mesh_term>Periodontal Pocket</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

